ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 66

Follistatin-Like Protein 1 Is An Important Regulator Of Chondrogenesis

Yury Chaly1, Sonja Smith2, Daniel Bushnell3, Brian Campfield4, Harry Blair5 and Raphael Hirsch6, 1Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, 2University of Iowa Carver College of Medicine, Iowa City, IA, 3Division of Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 4Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 5University of Pittsburgh School of Medicine, Pittsburgh, PA, 6Department of Pediatrics,, University of Iowa Carver College of Medicine, Iowa City, IA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: cartilage, chondrocytes, Mesenchymal stem cells and osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Biology and Pathology of Bone and Joint (Cartilage and Osteoarthritis)

Session Type: Abstract Submissions (ACR)

Background/Purpose: Chondrocytes play a pivotal role in osteoarthritis (OA) because they are the only cells in the articular cartilage that are responsible for maintenance of the extracellular matrix (ECM). Articular cartilage intrinsic regenerative capacity is strongly downregulated in humans with age. The use of mesenchymal stromal cells (MSC) is an attractive approach for cartilage repair because MSC are capable of proliferating and differentiating into chondrocytes in vitro. However, without detailed knowledge of how chondrogenic pathways are induced it has not been possible to produce true hyaline cartilage in vitro or in vivo, or to maintain cartilage growth. The present study was undertaken to determine whether follistatin-like protein 1 (FSTL1) regulates chondrogenic differentiation of MSC. We hypothesized that FSTL1 may enhance cell proliferation and anabolic activity in articular chondrocytes and, therefore, play an important role in maintaining cartilage homeostasis.

Methods: To study the role of FSTL1 in chondrogenesis, we made use of FSTL1 knockout (KO) mice generated in our laboratory. MSC were obtained from skulls of E18.5 embryos. Proliferative capacity of MSC was analyzed by flow cytometry using CFSE labeling. Differentiation of MSC into chondrocytes was carried out in a pellet culture system. Gene expression microarray analysis was performed on MSC isolated from FSTL1 KO and wild-type embryos. For signaling study, protein extracts from TGFb-stimulated MSC were analyzed for phospho (p)-SMAD3, p-p38 MAPK, p-AKT by Western blotting.

Results: Homozygous FSTL1 KO mice showed extensive skeletal defects, supporting a role for FSTL1 in chondrogenesis. FSTL1 KO embryos had decreased cellularity in the embryonic vertebral cartilage and FSTL1 KO MSC had reduced proliferative capacity. Microarray analysis of gene expression in FSTL1 KO MSC revealed dysregulation of multiple genes known to be involved in chondrogenesis, including COL1A2, COL2A1, COL10A1, SOX5, SOX9, TGFBR2, CTSK, GREM1, IGFBP4, WISP1. We also demonstrated that FSTL1-deficient MSC displayed defects in TGFb-induced differentiation into chondrocytes, including decreased production of ECM proteoglycans and reduced expression of type II collagen. TGFb-induced phosphorylation of SMAD3, p38 MAPK, and AKT were significantly decreased in FSTL1 KO cells.

Conclusion: These results demonstrate that FSTL1 is a crucial component of the regulatory mechanism controlling chondrocyte proliferation, differentiation, and expression of ECM molecules. Our findings may lead to the development of novel strategies for cartilage repair and provide new disease modifying treatments for OA.


Disclosure:

Y. Chaly,
None;

S. Smith,
None;

D. Bushnell,
None;

B. Campfield,
None;

H. Blair,
None;

R. Hirsch,

University of Pittsburgh,

9.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/follistatin-like-protein-1-is-an-important-regulator-of-chondrogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology